Inventor · disambiguated record
Dale L. Ludwig
Also filed as: LUDWIG DALE · LUDWIG DALE L · LUDWIG DALE LINCOLN
13 granted patents·28 pending applications·28 citations·filing 2000–2024
86Inventor score
Top patents by PatentIndex Score
41 records- 0188US10214586B2PD-L1 antibodiesLILLY CO ELI·Filed 2016·Granted Feb 26, 2019·9 cites·13 claims
- 0278US7638605B2Fully human antibodies directed against the human insulin-like growth factor-1 receptorIMCLONE LLC·Filed 2004·Granted Dec 29, 2009·13 cites·28 claims
- 0376US7968093B2Fully human antibodies directed against the human insulin-like growth factor-1 receptorIMCLONE LLC·Filed 2009·Granted Jun 28, 2011·3 cites·14 claims
- 0471US11912780B2Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapiesACTINIUM PHARMACEUTICALS INC·Filed 2018·Granted Feb 27, 2024·1 cites·25 claims
- 0567US9375488B2Compounds to fibroblast growth factor receptor-3 (FGFR3) and methods of treatmentIMCLONE LLC·Filed 2014·Granted Jun 28, 2016·2 cites·18 claims
- 0667US2025121105A1Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugatesACTINIUM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0765US12491274B2Radioconjugates targeting CD33 in the treatment of sarcomasACTINIUM PHARMACEUTICALS INC·Filed 2022·Granted Dec 9, 2025·0 cites·2 claims
- 0865US2025170259A1Compositions and methods for delivering therapeutic polynucleotides for exon skippingUNIV YALE·Filed 2023·Application pending·0 cites
- 0964US10279034B2Anti-PD-L1-anti-TIM-3 bispecific antibodiesLILLY CO ELI·Filed 2018·Granted May 7, 2019·0 cites·14 claims
- 1064US2024158528A1Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapiesACTINIUM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1163US11351251B2Anti-PD-L1-anti-TIM-3 bispecific antibodiesLILLY CO ELI·Filed 2019·Granted Jun 7, 2022·0 cites·7 claims
- 1263US2023303719A1Humanized 3e10 antibodies, variants, and antigen binding fragments thereofUNIV YALE·Filed 2023·Application pending·0 cites
- 1362US2025161484A1Compositions and methods for treating diseaseUNIV YALE·Filed 2023·Application pending·0 cites
- 1460US2025127917A1Compositions and methods for treating cancersUNIV YALE·Filed 2022·Application pending·0 cites
- 1558US2025205375A1Her3 radioimmunotherapy for the treatment of solid cancersACTINIUM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1656US12447218B1Radioconjugates directed to MHC-complexed antigens in cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Granted Oct 21, 2025·0 cites·4 claims
- 1756US2025073274A1Methods for treating cd33-positive hematological malignanciesACTINIUM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1856US2025281654A1Methods for treating cancer using combinations of epigenetic therapies and radioconjugate targeting agentsACTINIUM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1954US2023248855A1Her3 radioimmunotherapy for the treatment of solid cancersACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2053US2022251239A1Combination radioimmunotherapy and cd47 blockade in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2153US2022288244A1Combination radioimmunotherapy and cd47 blockade in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2252US2022211886A1Combination radioimmunotherapy and cd47 blockade in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2351US2024390532A1Radioimmunoconjugates targeting grp78 for use in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2451US2024216554A1Radioimmunoconjugates directed to nkg2d ligands for the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2550US6410723B1VDUP1 promoter and methods of use thereofIMCLONE SYSTEMS INC·Filed 2000·Granted Jun 25, 2002·0 cites·25 claims
- 2650US2019144544A1PD-L1 AntibodiesLILLY CO ELI·Filed 2019·Application pending·0 cites
- 2750US2025339571A1Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2849US2024226345A1Radioimmunoconjugates targeting calreticulin for use in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2949US2022143228A1Her3 radioimmunotherapy for the treatment of solid cancersACTINIUM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3049US2022072167A1Methods for Treating Cancer Using Combinations of PARP Inhibitors and Antibody RadioconjugatesACTINIUM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3148US2020338219A1Molecules and their derivatives directed aganist cd45ACTINIUM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3248US2024197931A1Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cellsACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3348US2022211885A1Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseasesACTINIUM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3448US2023302168A1Dr5 radioimmunotherapy in the treatment of solid cancersACTINIUM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3548US2023390424A1Trophoblast glycoprotein radioimmunotherapy for the treatment of solid cancersACTINIUM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3647US7972600B2IGF-IR antagonists as adjuvants for treatment of prostate cancerIMCLONE LLC·Filed 2007·Granted Jul 5, 2011·0 cites·13 claims
- 3746US11203640B2Checkpoint inhibitor bispecific antibodiesLILLY CO ELI·Filed 2018·Granted Dec 21, 2021·0 cites·5 claims
- 3846US2022008570A1Combination of radioimmunotherapy and immune checkpoint therapy in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3942US2022125962A1Antibodies Conjugated With Actinium-225 and Actinium-227, and Related Compositions and MethodsACTINIUM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4041US2022202967A1Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseasesACTINIUM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4139US10711066B2Anti-canine platelet derived growth factor receptor alpha antibodyELANCO US INC·Filed 2017·Granted Jul 14, 2020·0 cites·6 claims
Join the waitlist — get patent alerts
Get an alert when Dale L. Ludwig files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →